S17 Ep38: FDA Approval Insights: Decitabine/Cedazuridine Plus Venetoclax for AML: With Courtney D. DiNardo, MD, MSCE

In today’s episode, we spoke with Courtney D. DiNardo, MD, MSCE, a professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center and an associate member of The University of Texas Graduate School of Biomedical Sciences in Houston.In our exclusive interview, Dr DiNardo discussed the May 2026 FDA approval of decitabine (Dacogen) and cedazuridine (Inqovi) plus venetoclax (Venclexta) in patients with newly diagnosed acute myeloid leukemia (AML). DiNardo outlined numerous important facets of the approval, including its effects on the treatment paradigm, which patients will benefit most, safety considerations with the regimen, and quality of life advantages that have been observed with the combination. Furthermore, she discussed how this approval fits into a larger shift for the AML treatment paradigm and how the AML research field can build upon the approval of this regimen.